Hajime Kurosaki

This inventor holds 3 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Tottori University, Astellas Pharma Gmbh, Evolve Biotherapeutics Co., Ltd.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hajime Kurosaki. Retrieved from https://idiyas.com/inventor/hajime-kurosaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

Evolve Biotherapeutics Co., Ltd.

patent

4. 1 out of 4

National University Corporation Tottori University

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12409198 - Vaccinia virus that induces cell fusion and use thereof (2025-09-09),

2. 11344589 - Genetically engineered vaccinia viruses (2022-05-31),

3. 10370647 - Host regulatory factor that enhances replication and/or propagation of vaccinia virus (2019-08-06),

Title: Hajime Kurosaki: Innovator in Vaccinia Virus Research

Introduction

Hajime Kurosaki is a notable inventor based in Yonago, Japan. He has made significant contributions to the field of virology, particularly in the development of vaccinia viruses for therapeutic applications. With a total of 3 patents, his work focuses on innovative methods to induce cell fusion and combat cancer.

Latest Patents

Kurosaki's latest patents include groundbreaking inventions such as a vaccinia virus that induces cell fusion between infected cells. This invention provides a method for producing a vaccinia virus that is deprived of the K2L gene or the HA gene, mutated to induce cell fusion and cell death. Another significant patent involves genetically engineered vaccinia viruses that are effective in preventing or treating cancer. This recombinant virus lacks functions of VGF and O1L and includes a gene encoding B5R with a deleted SCR domain. Additionally, he has developed a combination kit of two vaccinia viruses, each encoding IL-7 and IL-12, for enhanced therapeutic use.

Career Highlights

Throughout his career, Hajime Kurosaki has worked with esteemed institutions such as Tottori University and Astellas Pharma GmbH. His research has been pivotal in advancing the understanding and application of vaccinia viruses in medical treatments.

Collaborations

Kurosaki has collaborated with notable colleagues, including Takafumi Nakamura and Motomu Nakatake, contributing to the advancement of his research and innovations.

Conclusion

Hajime Kurosaki's work in the field of vaccinia virus research exemplifies the impact of innovative thinking in medicine. His patents reflect a commitment to developing effective treatments for serious health conditions.

Profile summary based on public USPTO records.